Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2; [Персистенция новой коронавирусной инфекции у пациентки с первичной крупноклеточной В-клеточной лимфомой центральной нервной системы с оценкой гуморального иммунного ответа против SARS-CoV-2]

Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. there is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. this article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large b-cell lymphoma during chemotherapy. © 2024 ABV-press Publishing House. All rights reserved.